secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2021-10-08T23:59:59+00:00
Accession:  0000950170-21-002075
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics reports CTX-009 Phase 1 data: 19% ORR at RP2D in heavily pre-treated tumors
--------------------------------------------------------------------------------

- CTX-009 monotherapy achieved 19% ORR (3/16) at RP2D (10.0-12.5 mg/kg) and 69% DCR.
- Across all doses, ORR was 8% (4 partial responses) and DCR was 62% in heavily pre-treated patients (median 3 prior lines).
- Treatment well tolerated; no dose-limiting toxicities; hypertension in 38% (17/45), 7 Grade 3.
- 94% of colorectal and 58% of gastric patients had prior anti-VEGF therapy (bevacizumab/ramucirumab).
- Phase 1b combo and Phase 2 studies underway; Compass holds global rights except S. Korea and China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000095017021002075/0000950170-21-002075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000095017021002075/cmpx-20211008.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-002075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer